To investigate the relationship between sleep disturbance, fatigue, and urinary incontinence (UI) and overactive bladder (OAB) symptoms among patients with OAB.Patients who were diagnosed with OAB and age-matched control subjects without OAB were enrolled. Sleep disturbance and fatigue symptoms were assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) short forms. UI and OAB symptoms were assessed using the International Consultation on Incontinence Questionnaire—Urinary Incontinence (ICIQ-UI), the International Consultation on Incontinence Questionnaire—Overactive Bladder (ICIQ-OAB), the Overactive Bladder Questionnaire (OAB-q), the Urogenital Distress Inventory Short Form (UDI-6), and the Incontinence Impact Questionnaire Short Form (IIQ-7). Psychosocial health (depression, anxiety, and perceived stress level) was also assessed.Patients with OAB reported a significantly greater sleep disturbance compared with controls (PROMIS 8b T-scores: 54.3 ± 10.3 vs 43.8 ± 9.2). Patients with OAB also reported a significantly greater fatigue compared with controls (PROMIS 7a T-scores: 54.7 ± 9.6 vs 46.0 ± 6.4). After adjusting for nocturia, the differences in sleep disturbance between OAB and controls became insignificant (P = .21), whereas the differences in fatigue between OAB and controls remained significant (P = .014). Among patients with OAB, there were positive correlations between sleep disturbance and the severity of OAB symptoms (ICIQ-OAB), poorer health-related quality of life (OAB-q QOL), the severity of UI symptoms (ICIQ-UI), greater incontinence impact (IIQ-7), and urinary bother (UDI-6). Positive correlations were also observed between fatigue and worse UI and OAB symptoms and quality of life. Both sleep disturbance and fatigue were associated with poor psychosocial health (depression, anxiety, and higher stress level) among patients with OAB.Sleep disturbance and fatigue are present in substantial percentages of patients with OAB. Among patients with OAB, sleep disturbance and fatigue were associated with more severe UI and OAB symptoms, worse health-related quality of life, and poorer psychosocial health.
Additional file 1. Table S1: Detailed summary of RRBS QC parameters and patient data from cohort 1, cohort 2, and normal kidney. Table S2: List of differentially methylated CpGs and the gene(s) they are associated with from cohort 1. Table S3: Full list of GO biological pathways to which the 5929 DMCpGs were associated using GREAT. Table S4: List of kidney-related GO biological pathways to which the 5929 DMCpGs were associated using GREAT. Table S5: Full list of canonical pathways to which the 5744 genes obtained from GREAT were associated in IPA. Table S6: List of differentially methylated CpGs and the gene(s) they are associated with from cohort 2. Table S7: List of 43 CpGs separating aggressive from less aggressive KIRC tumors. Table S8: List of PCR and pyrosequencing primers used in this study.
With the increasing world population and living standards the demand for mineral and energy resources continues to grow. Future exploration will need to target resources at increasing depths and in areas with cover, and will require an improved understanding of mineral and energy systems and advances in exploration methods and approaches. The Economic Geology Research Centre (EGRU) at James Cook University has organized the FUTORES II conference to summarise recent developments in the exploration and understanding of major types of mineral deposits, to examine the key issues and techniques critical to future minerals and energy exploration, and to discuss the way forward. The conference is being held in tropical Townsville, Queensland, Australia, on 4-7 June 2017. It is following on from the inaugural and highly successful FUTORES conference held in Townsville in 2013.FUTORES II will bring together researchers, explorers and government agencies to address issues related to the sustainable supply and utilisation of mineral and energy resources. The conference has three symposia: the David Groves Symposium - New Insights in Mineral Deposit Understanding, the New Technologies and Approaches in Mineral Exploration Symposium, and the Tectonics, Basins and Resources Symposium. The conference is convened by EGRU, an organisation that was established in 1982 to strengthen the links between research and exploration, to promote exploration-oriented research, and to facilitate knowledge transfer. EGRU has a track record of organising successful major conferences to facilitate the exchange of knowledge and ideas and to stimulate new ideas for cutting-edge research and exploration. The Hydrothermal Odyssey conference in 2001, and the STOMP (Structure, Tectonics and Ore Mineralization Processes) conference in 2005, both attracted over 200 participants. In 2009 EGRU collaborated with the SGA to host the tenth biennial SGA conference in Townsville - Smart Science for Exploration and Mining - which attracted over 480 delegates from around the world. In 2013 the first FUTORES conference attracted around 250 participants from 15 countries. FUTORES II is looking to be equally successful and has so far attracted around 265 registrants. This conference abstract volume contains 134 abstracts covering a wide range of topics related to mineral and energy resources, tectonics and metallogenesis. The abstracts have been reviewed and edited by the Editorial Committee and, in this volume, are organised in alphabetical order of the first author. We thank the delegates for their abstracts and the reviewers for ensuring the quality of the abstract volume.
Hidradenocarcinoma is a rare malignancy of the sweat glands with only a few cases reported in literature. The management of these tumors is based on the extent of disease with local disease managed with surgical resection. These can tumors carry a high potential of lymphatic and vascular spread and local and distant metastases are not uncommon. Given the rarity of the tumor and lack of genetic and clinical data about these tumors, there is no consensus on the proper management of metastatic disease. Here in we report the first case of metastatic hidradenocarcinoma with detailed molecular profiling including whole exome sequencing. We identified mutations in multiple genes including two that are potentially targetable: PTCH1 and TCF7L1. Further work is necessary to not only confirm the presence of these mutations but also to confirm the clinical significance.
447 Background: Components of the peripheral blood counts (PBC) are associated with poor prognosis in patients diagnosed with non-metastatic clear cell renal cell carcinoma (ccRCC). Related to this, higher tumor expression of programmed death ligand one (PDL1) is also associated with poor ccRCC prognosis. Herein, we utilize a large cohort of patients undergoing nephrectomy for localized ccRCC to evaluate the association of PBC with tumor expression of PDL1. Secondarily, we examine the association of PBC and relapse free survival (RFS) after adjusting for age and PDL1 expression. Methods: Through chart review, we obtained PBC values at time of nephrectomy for patients enrolled in the Mayo Clinic Renal Registry from 1990-2009 who were treated for localized (M0) ccRCC including the following: hemoglobin (HGB), white blood cell (WBC), absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute eosinophil count (AEC), absolute monocyte count (AMC), and platelets (PLT). We determined tumor PDL1 expression as a continuous variable (% of positive PDL1 tumor cells) using the 5H1 antibody on archived tissues. We analyzed the correlation of PBC values with PDL1 expression as a continuous variable using a linear estimate. To evaluate the association of PBC values with RFS after adjusting for PDL1 expression, we employed multivariate Cox regression models. Results: A total of 706 ccRCC patients had available PDL1 expression and PBC. PDL1 expression was inversely associated with HGB (linear estimate of -0.02, p<0.001) and positively associated with platelets (linear estimate 1.73, p<0.001) whereas there was no association with PDL1 with WBC, ANC, AEC, or AMC. After adjusting for age and PDL1 expression, a higher HGB (HR=0.87, p<0.001), higher ALC (HR 0.68, p=0.003), and higher AEC (HR 0.12, p=0.002) were all associated with improved relapse free survival. Conversely, higher PLT was associated with decreased RFS (HR 1.002, p<0.001). Conclusions: PDL1 expression is associated with decreased HGB and increased PLT at the time of nephrectomy. After adjusting for PDL1 expression and age, higher HGB, ALC, and AEC are associated with improved RFS, while higher platelets are associated with decreased RFS.
e15590 Background: Peripheral blood counts (PBC) such as anemia and elevated platelets are associated with a worse prognosis in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC). The association of PBC in patients with non-metastatic ccRCC remains unclear. We performed a retrospective analysis to assess the impact of PBC on RCC-specific survival (RCC-SS) and relapse free survival (RFS). Methods: We abstracted available PBC values within 30 days of nephrectomy for all pts enrolled in the Mayo Clinic Renal Registry from 1990-2009 treated for localized (M0) ccRCC. PBC values included hemoglobin (HGB), white blood cell (WBC), absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute eosinophil count (AEC), absolute monocyte count (AMC), and platelets (PLT). To correct for skewed data, we transformed PBC values via the square root transform. We analyzed the correlation of PBC values with both RFS and RCC-SS using age-adjusted Cox regression models. We then assessed the independent prognostic value of PBC after further adjusting for the validated Mayo SSIGN score that incorporates tumor size, stage, grade, and tumor necrosis. Results: Of 1,657 pts in the renal registry, 1,265 (76.3%) had available PBC from the time of diagnosis. PBC strongly associated with the Mayo SSIGN score. Prior to adjusting for the Mayo SSIGN score, all PBC associated with both RCC-SS and RFS. After adjusting for the Mayo SSIGN score, no PBC values remained significant in terms of RCC-SS and low ANC remained minimally associated with decreased RFS (see Table). Conclusions: PBC values strongly associate with the Mayo SSIGN score but predictably do not add independent prognostic information. Given this association, improved understanding of how ccRCC influences PBC could lead to novel therapeutic options. Marker Prior to adjusting for SSIGN After adjusting for SSIGN RCC-SS RFS RCC-SS RFS HR P HR P HR P HR P HGB 0.18 <0.001 0.25 <0.001 0.97 0.89 1.29 0.17 WBC 1.17 0.004 1.17 0.003 1.04 0.61 0.97 0.73 PLT 1.16 <0.001 1.13 <0.001 1.00 0.68 0.99 0.32 ANC 1.72 <0.001 1.44 <0.001 0.96 0.79 0.71 0.02 ALC 0.40 0.001 0.45 <0.001 0.84 0.54 0.81 0.37 AMC 5.89 <0.001 4.12 <0.001 1.33 0.57 0.89 0.76 AEC 0.39 0.030 0.45 0.033 0.74 0.49 0.71 0.36
